摘要
【目的】探讨美沙拉嗪肠溶片对肠易激综合征（IBS）患者水通道蛋白（AQP）3、4、8的影响和临床意义。【方法】在本院住院的IBS患者151例，随机分成两组，研究组78例，对照组73例。对照组采用常规治疗，抗胆碱能药物配合纤维素应用。研究组在对照组的治疗基础上应用美沙拉嗪肠溶片口服1．0g，3次／日；疗程4周，采用ELISA法测定两组患者治疗前后AQP-3、AQP-4和AQP-8的变化。【结果】与治疗前比较，治疗后两组AQP-3、AQP-4和AQP-8均明显增加，且差异有显著性（P〈O．05），治疗后研究组与对照组比较AQP-3、AQP-4和AQP-8增加更明显，且差异有显著性（P〈0．05）。【结论】美沙拉嗪肠溶片治疗IBS效果良好，可能是通过调节AQP-3、AQP-4和AQP-8水平改善症状，值得临床推广应用。
[Objective] To explore the effect of mesalazine enteric-coated tablets（HuiDi） on aquaporin （AQP） 3, AQP4 and AQP8 in patients with intestinal stress syndrome. [Methods] Totally 151 patients with intestinal stress syndrome in our hospital from Jan. 2011 to June 2012 were chosen and randomly divided into research group（ n = 78） and control group（ n = 73）. The control group received routine treatment i. e anticho- linergic drug combined with cellulose. Basis on the treatment of control group, the research group was given o- ral HuiDi 1.0g for 3 times a day. The course of treatment was 4 weeks. ELISA method was used to measure the changes of AQP3, AQP4 and AQP8 in patients of two groups. [Results] Compared with before treat- ment, AQP3, AQP4 and AQP8 of two groups obviously increased, and there was significant difference（ P % 0.05）. After treatment, AQP3, AQP4 and AQP8 in research group increased more obviously than those in control group, and there was significant difference（ P d0.05）. [Conclusion] HuiDi for the treatment of intes- tinal stress syndrome has good efficacy, which may improve the syndromes by regulating AQP3, AQP4 and AQPS. Therefore it is worthy of clinical promotion in clinical practice.
出处
《医学临床研究》
CAS
2013年第4期629-631,共3页
Journal of Clinical Research
